abiraterone acetate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: abiraterone acetate
• 英文别名: 17-(3-Pyridyl)-5,16-androstadien-3beta-acetate；(10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl) acetate
• 化学式: C₂₆H₃₃NO₂
• 分子量: 391.554
• InChiKey: UVIQSJCZCSLXRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  abiraterone acetate 在 lithium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 生成 abiraterone
  参考文献：
  名称：

  Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway

  摘要：

  DOI：

  10.1021/acs.molpharmaceut.3c00621

文献信息

• [EN] PRODRUGS OF ABIRATERONE<br/>[FR] PROMÉDICAMENTS D'ABIRATÉRONE
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2021100019A1

  公开（公告）日：2021-05-27

  The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers, or pharmaceutically acceptable salt(s) thereof as prodrugs of abiraterone. The present invention also describes method of making such compounds, pharmaceutical compositions comprising such compounds and the use of the compounds of formula (I).

  本发明涉及式(I)的化合物，或其同位素形式、立体异构体、互变异构体或其药学上可接受的盐作为阿比特龙的前药。本发明还描述了制备这种化合物的方法，包含这种化合物的药物组合物以及式(I)化合物的用途。
• ACETATIC ABIRATERONE TRIFLUOROACETATE AND PREPARATION METHOD AND APPLICATION OF SAME
  申请人：SHANGHAI CDYMAX PHARMACEUTICALS CO., LTD.

  公开号：US20150133652A1

  公开（公告）日：2015-05-14

  Provided are acetaic abiraterone trifluoroacetate, a preparation method and an application of same. The acetaic abiraterone trifluoroacetate is obtained through a salt-forming reaction between acetaic Abiraterone and trifluoroacetic acid. The acetaic abiraterone trifluoroacetate undergoes self-purification through recrystallization, and dissociation and recrystallization are performed on the purified abiraterone acetate trifluoroacetate, so that the obtained acetaic abiraterone has a high purity, a high yield and stable quality, and is capable of meeting the requirement for mass production of acetaic abiraterone.

  提供了乙酸醋酮三氟乙酸酯、其制备方法和应用。乙酸醋酮三氟乙酸酯是通过乙酸醋酮和三氟乙酸之间的盐形成反应获得的。乙酸醋酮三氟乙酸酯通过重结晶进行自净化，对纯化后的乙酸醋酮三氟乙酸酯进行解离和重结晶处理，从而获得高纯度、高产率和稳定质量的乙酸醋酮，能够满足乙酸醋酮的大规模生产要求。
• [EN] PROCESS FOR THE PREPARATION OF ABIRATERONE AND ABIRATERONE ACETATE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ABIRATÉRONE ET D'ACÉTATE D'ABIRATÉRONE
  申请人：IND CHIMICA SRL

  公开号：WO2015015246A1

  公开（公告）日：2015-02-05

  The present invention relates to a novel process for the synthesis of abiraterone, and in particular of abiraterone acetate, compound of formula (I) reported below: N O (I) which has pharmacological activity useful tor slowing down the progression of prostate cancer at an advanced stage. The process is characterised by an intermediate step wherein DHEA-acetate is triflated using Ar-N(OTf)2 as the triflation reagent.

  本发明涉及一种合成醋酸阿比特龙的新工艺，特别是合成下述式（I）化合物的工艺：N O（I），该化合物具有对延缓晚期前列腺癌进展有用的药理活性。该工艺的特点是在中间步骤中，使用Ar-N(OTf)2作为三氟甲基化试剂，对DHEA-醋酸酯进行三氟甲基化。
• ABIRATERONE AND ANALOGS THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CORTISOL OVERPRODUCTION
  申请人：CORTENDO AB (PUBL)

  公开号：US20150337003A1

  公开（公告）日：2015-11-26

  Novel analogs of abiraterone and methods of treating diseases associated with the overproduction of cortisol, such as Cushing's syndrome, obesity, headache depression, hypertension, diabetes mellitus type II, metabolic syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, stroke or incidentalomas, by administering an effective amount of abiraterone or analogs thereof to a patient in need thereof are described.

  描述了一种治疗与皮质醇过度产生相关的疾病的方法，如库欣综合症、肥胖、头痛、抑郁症、高血压、糖尿病II型、代谢综合征、假性庫欣症、认知障碍、痴呆、心力衰竭、肾功能衰竭、牛皮癣、青光眼、心血管疾病、中风或偶发瘤，通过向需要的患者施用有效剂量的阿比特龙或其类似物。
• COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE
  申请人：Lin Kui

  公开号：US20150064171A1

  公开（公告）日：2015-03-05

  The invention provides combinations comprising a) compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 5 , R 10 , and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

  本发明提供组合物，其中包括a)式（I）化合物或其药学上可接受的盐，其中R1、R2、R5、R10和A的值在规范中定义；和b)选择自5-FU、铂类药物、亚叶酸、伊立替康、多西他赛、多柔西汀、吉西他滨、SN-38、卡培他滨、替莫唑胺、紫杉醇、贝伐珠单抗、珀妥珠单抗、他莫昔芬、雷帕霉素和拉帕替尼的一种或多种药剂。这些组合物特别适用于治疗高增殖性疾病，如癌症。